241 related articles for article (PubMed ID: 19689374)
1. Development of extracellular signal-regulated kinase inhibitors.
Burkhard K; Smith S; Deshmukh R; MacKerell AD; Shapiro P
Curr Top Med Chem; 2009; 9(8):678-89. PubMed ID: 19689374
[TBL] [Abstract][Full Text] [Related]
2. Characterization of ATP-independent ERK inhibitors identified through in silico analysis of the active ERK2 structure.
Chen F; Hancock CN; Macias AT; Joh J; Still K; Zhong S; MacKerell AD; Shapiro P
Bioorg Med Chem Lett; 2006 Dec; 16(24):6281-7. PubMed ID: 17000106
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel extracellular signal-regulated kinase docking domain inhibitors.
Hancock CN; Macias A; Lee EK; Yu SY; Mackerell AD; Shapiro P
J Med Chem; 2005 Jul; 48(14):4586-95. PubMed ID: 15999996
[TBL] [Abstract][Full Text] [Related]
4. Rational Design and Synthesis of Diverse Pyrimidine Molecules Bearing Sulfonamide Moiety as Novel ERK Inhibitors.
Halawa AH; Eskandrani AA; Elgammal WE; Hassan SM; Hassan AH; Ebrahim HY; Mehany ABM; El-Agrody AM; Okasha RM
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31717402
[TBL] [Abstract][Full Text] [Related]
5. Mitogen activated protein (MAP) kinases: development of ATP and non-ATP dependent inhibitors.
Hancock CN; Macias AT; Mackerell AD; Shapiro P
Med Chem; 2006 Mar; 2(2):213-22. PubMed ID: 16787369
[TBL] [Abstract][Full Text] [Related]
6. Selective in vivo inhibition of mitogen-activated protein kinase activation using cell-permeable peptides.
Kelemen BR; Hsiao K; Goueli SA
J Biol Chem; 2002 Mar; 277(10):8741-8. PubMed ID: 11756441
[TBL] [Abstract][Full Text] [Related]
7. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
Yang R; Piperdi S; Gorlick R
Clin Cancer Res; 2008 Oct; 14(20):6396-404. PubMed ID: 18927278
[TBL] [Abstract][Full Text] [Related]
8. Substrate recognition domains within extracellular signal-regulated kinase mediate binding and catalytic activation of mitogen-activated protein kinase phosphatase-3.
Nichols A; Camps M; Gillieron C; Chabert C; Brunet A; Wilsbacher J; Cobb M; Pouyssegur J; Shaw JP; Arkinstall S
J Biol Chem; 2000 Aug; 275(32):24613-21. PubMed ID: 10811804
[TBL] [Abstract][Full Text] [Related]
9. Computational design, chemical synthesis, and biological evaluation of a novel ERK inhibitor (BL-EI001) with apoptosis-inducing mechanisms in breast cancer.
Liu B; Fu L; Zhang C; Zhang L; Zhang Y; Ouyang L; He G; Huang J
Oncotarget; 2015 Mar; 6(9):6762-75. PubMed ID: 25742792
[TBL] [Abstract][Full Text] [Related]
10. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N
Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705
[TBL] [Abstract][Full Text] [Related]
11. Dual binding site inhibitors of B-RAF kinase.
Wolin RL; Bembenek SD; Wei J; Crawford S; Lundeen K; Brunmark A; Karlsson L; Edwards JP; Blevitt JM
Bioorg Med Chem Lett; 2008 May; 18(9):2825-9. PubMed ID: 18434146
[TBL] [Abstract][Full Text] [Related]
12. Development and implementation of three mitogen-activated protein kinase (MAPK) signaling pathway imaging assays to provide MAPK module selectivity profiling for kinase inhibitors: MK2-EGFP translocation, c-Jun, and ERK activation.
Nickischer D; Laethem C; Trask OJ; Williams RG; Kandasamy R; Johnston PA; Johnston PA
Methods Enzymol; 2006; 414():389-418. PubMed ID: 17110204
[TBL] [Abstract][Full Text] [Related]
13. Bradykinin-regulated interactions of the mitogen-activated protein kinase pathway with the endothelial nitric-oxide synthase.
Bernier SG; Haldar S; Michel T
J Biol Chem; 2000 Sep; 275(39):30707-15. PubMed ID: 10899167
[TBL] [Abstract][Full Text] [Related]
14. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
15. Computational insights for the discovery of non-ATP competitive inhibitors of MAP kinases.
Schnieders MJ; Kaoud TS; Yan C; Dalby KN; Ren P
Curr Pharm Des; 2012; 18(9):1173-85. PubMed ID: 22316156
[TBL] [Abstract][Full Text] [Related]
16. Current developments in extracellular-regulated protein kinase (ERK1/2) inhibitors.
Niu Y; Ji H
Drug Discov Today; 2022 May; 27(5):1464-1473. PubMed ID: 35104620
[TBL] [Abstract][Full Text] [Related]
17. Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control.
Aronov AM; Tang Q; Martinez-Botella G; Bemis GW; Cao J; Chen G; Ewing NP; Ford PJ; Germann UA; Green J; Hale MR; Jacobs M; Janetka JW; Maltais F; Markland W; Namchuk MN; Nanthakumar S; Poondru S; Straub J; ter Haar E; Xie X
J Med Chem; 2009 Oct; 52(20):6362-8. PubMed ID: 19827834
[TBL] [Abstract][Full Text] [Related]
18. A high throughput assay to identify substrate-selective inhibitors of the ERK protein kinases.
Miller CJ; Muftuoglu Y; Turk BE
Biochem Pharmacol; 2017 Oct; 142():39-45. PubMed ID: 28647489
[TBL] [Abstract][Full Text] [Related]
19. Use of docking peptides to design modular substrates with high efficiency for mitogen-activated protein kinase extracellular signal-regulated kinase.
Fernandes N; Bailey DE; Vanvranken DL; Allbritton NL
ACS Chem Biol; 2007 Oct; 2(10):665-73. PubMed ID: 17918909
[TBL] [Abstract][Full Text] [Related]
20. TGF-alpha increases human mesenchymal stem cell-secreted VEGF by MEK- and PI3-K- but not JNK- or ERK-dependent mechanisms.
Wang Y; Crisostomo PR; Wang M; Markel TA; Novotny NM; Meldrum DR
Am J Physiol Regul Integr Comp Physiol; 2008 Oct; 295(4):R1115-23. PubMed ID: 18685072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
